Updating neuropathology and neuropharmacology of monoaminergic systems.
This article is part of a themed section on Updating Neuropathology and Neuropharmacology of Monoaminergic Systems. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v173.13/issuetoc.
Biomedical Sciences Research Centre, University of St Andrews, St Andrews, UK.
Rona R
RR
Ramsay
Institut of Neurodegenerative Disease, UMR CNRS 5293, Bordeaux cedex, France.
Philippe
P
De Deurwaerdère
Neuroscience Division, School of Bioscience, Cardiff University, Cardiff, UK.|Department of Physiology and Biochemistry, University of Malta, Msida, Malta.
Giuseppe
G
Di Giovanni
D000818:Animals; D015306:Biogenic Monoamines / Q000494:pharmacology*; D003863:Depression / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009480:Neuropharmacology
D015306:Biogenic Monoamines